Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM24 plus atezolizumab in EGFR-expressing advanced/metastatic cancers
2024-511999-32-00Phase 2Completed
- Sponsor
- Affimed
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of AFM24 and atezolizumab in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more (8 arms), sponsored by Affimed. Primary endpoints: Dose-limiting toxicities in Cycle 1 (Phase 1) and Objective response rate (Phase 2a). Started Apr 2024; status: completed.
02
Drugs
AFM24atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)Hepatobiliary adenocarcinoma
Beyond the preview
Go deeper on 2024-511999-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511999-32-00.